New Sprayable Gel Could Revolutionize Battlefield Medicine

What Happened?

A new sprayable gel developed by the Korean Institute of Advanced Science and Technology has the potential to revolutionize battlefield medicine in treating wounded soldiers. The new spray instantly turns into a gel on contact with blood, allowing it to seal wounds and stop bleeding for large or jagged wounds of the type commonly experienced by soldiers in combat.

According to New Atlas, the substance is made from three natural ingredients: alginate, which can be extracted from brown seaweed; gellan gum, a natural thickener made through bacterial fermentation; and chitosan, a powder made from the exoskeletons of crustaceans.

The alginate and gellan gum turn from a powder into a gel in the presence of blood immediately upon contact, which mimics the clotting of blood. 

Why it Matters

In the past half-century, thanks to advances in battlefield medicine, many previously unsurvivable wounds can now be treated, allowing wounded soldiers to survive. Despite that progress, the most common cause of death from combat wounds is still exsanguination, or blood loss.

When a combatant suffers a gunshot wound or is wounded by explosives, the loss of limbs or deep penetrating flesh wounds often severs major arteries leading to rapid and fatal blood loss.

The Surging AI Everyone Wants In On

$60M+ raised. 14,000+ investors. Valuation up 5,000%+ in 4 years*. Shares still only $0.85.

Backed by Adobe and insiders from Google, Meta, and Amazon, RAD Intel has its Nasdaq ticker ($RADI) reserved and a leadership team with $9 Billion+ in M&A transactions under their belt.

A who’s-who roster of Fortune 1000 clients and agency partners are already using their award-winning AI platform with recurring seven-figure partnerships in place.

Spotlighted in Fast Company, RAD Intel was described in a sponsored feature as “a groundbreaking step for the Creator Economy".  Lots to like here;  sales contracts have doubed in 2025 vs. 2024.  Industry consolidation is exploding — 240 AI deals worth $55B in just six months.

Join early, diversify, and participate in RAD Intel’s upside today.

Own the layer everyone will build on.

👉 Invest Early -- Shares Just $0.85

The severing of major arteries can lead to death by blood loss in minutes, which is often less time than it takes to get wounded soldiers from the battlefield to hospitals or other medical providers. Stopping blood loss can be particularly challenging when dealing with jagged or irregularly shaped wounds, because traditional bandages or tourniquets don’t work well on those types of injuries. The inability to stop blood loss quickly often contributes to loss of life from combat wounds. 

In initial testing, the new gel, which has yet to be named, was able to hold several times its own weight in blood, meaning it could stop bleeding even when the wounds were extensive or major. Even if the gel only held for short time periods, that could still be enough to allow wounded soldiers to be transported from the battlefield to hospitals for treatment. 

During the nineteenth and early twentieth centuries, in many wars, more soldiers died from infections or disease than from enemy fire.

Advances in germ theory and antibiotics provided new and more effective ways to treat common illnesses and infections, so that by the end of the Second World War, more soldiers died from enemy fire than from disease or infection. The new gel could once again revolutionize battlefield medicine by giving field medics a way to quickly stop blood loss in wounded soldiers.

How it Affects You

Advances in battlefield medicine often find their way into civilian life. The new sprayable gel could also be used to help save the lives of a wide range of trauma patients, from those injured in automobile crashes to workplace injuries involving heavy machinery.

*Disclaimer: This is a paid advertisement for RAD Intel made pursuant to Regulation A+ offering and involves risk, including the possible loss of principal. The valuation is set by the Company and there is currently no public market for the Company's Common Stock. Nasdaq ticker “RADI” has been reserved by RAD Intel and any potential listing is subject to future regulatory approval and market conditions. Brand references reflect factual platform use, not endorsement. Investor references reflect factual individual or institutional participation and do not imply endorsement or sponsorship by the referenced companies. Please read the offering circular and related risks at invest.radintel.ai.